Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessPharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study
In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients...
-
Article
Immunotherapeutic strategies in kidney cancer—when TKIs are not enough
The management of metastatic clear-cell renal-cell carcinoma has been revolutionized by the approval of targeted therapies. These targeted therapies have, however, been unable to provide robust complete respon...